Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai has released preliminary results from an open-label, global, single-arm Phase II study evaluating its multi-targeted kinase inhibitor lenvatinib (E7080).
Subscribe to our email newsletter
The results from the trial showed an objective response rate (ORR) of 59% (34/58, 95% CI: 45-71), based on an updated investigator assessment, in patients with advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).
The involved around 58 patients with advanced RAI refractory DTC whose disease had progressed during the prior 12 months.
Currently, Eisai is engaged in advancing its products like Halaven, lenvatinib and farletuzumab (MORAb-003), for the treatment of breast, ovarian, thyroid, endometrial and other types of cancer in the women’s oncology arena.